Given the factthat 10 μM doses of Δ2-troglitazonesignificantly affect TGF-β1 release (Figure 1(d)) and glioma cellmotility (Figure 2) but not glioma cell viability (Figure 1(c)), these data suggest that glioma cellmigration is an essential requirement for glioma progression in a system closely resembling extracellular matrix environment presentin the brain. Here, TGFB1 is linked to central nervous system cancer.